Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Last 25 million dollar dilution

<< Previous

Bullboard Posts

Next >>

Comment by Pragmatiston Feb 18, 2021 2:11am

218 Views

Post# 32593025

RE:RE:RE:Last 25 million dollar dilution

RalphRalph wrote:
The fact that they had to offer warrants is not a good sign. When demand is very high, no warrants are needed to sweeten the deal. The terms of the warrants are also unfavorable - $7.50 / 3 years / no acceleration clause.

The constant need for warrants in their raises reflects the cost of management's inability to get the company onto the NASDAQ. From a business standpoint, their capital management and execution of capital raises has been sub-par. Their current cash position (including bought deal $) is also not enough to fully fund Phase 3 & maintain operations/pipeline development during that stretch of years.

I appreciate your posts, RR. I don't necessarily agree with everything that you have said, but your arguments are fundamentally sound and something that we all should take into consideration. I do. Pls keep sharing your thoughts.

Alex1967 wrote: They have $16 million in cash and cash equivalent. Keep in mind they had to do a lot of animal testing on (absorption, metabolism, and excretion) before they can apply for IND for phase 3.
The extra cash allows them to negotiate with potential partners from point of strength.